指南与共识头颈外科

美国头颈学会内分泌外科分会与国际甲状腺肿瘤学组关于甲状腺癌突变检测的共识声明:定义晚期甲状腺癌及其靶向治疗

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.
指南 / 共识 · Head Neck · 2022-03-11

该共识由美国头颈学会内分泌外科分会与国际甲状腺肿瘤学组组织专家小组,通过文献回顾和改良德尔菲法制定,围绕晚期甲状腺癌的多学科管理、分子评估及靶向全身治疗提出20条最佳实践声明,并给出晚期甲状腺癌的共识定义。

要点

  • 共识定义晚期甲状腺癌并阐述其分子评估与靶向全身治疗。
  • 采用改良德尔菲法评估作者小组所制定声明的共识程度。
  • 共提供20条涉及多学科管理、分子评估和靶向全身治疗的声明。

核心结论

  • 随着甲状腺癌靶向治疗选择增多,有必要就晚期疾病的共识定义以及分子检测和可用靶向全身治疗的效用制定声明。

研究设计与样本

  • 组建专家小组,进行文献回顾,制定最佳实践声明,并应用改良德尔菲法评估作者小组所制定声明的共识程度。

主要发现

  • 呈现了对甲状腺肿瘤发生分子层面当前认识的综述,并定义了晚期甲状腺癌的特征。

关键数值与推荐

  • 提供了20条声明,主题包括晚期甲状腺癌的多学科管理、分子评估和靶向全身治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence-based statement on the definition of advanced thyroid cancer and its targeted systemic treatment. METHODS: An expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel. RESULTS: A review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided. CONCLUSIONS: With the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Shonka DC, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022. PMID: 35274388. doi:10.1002/hed.27025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。